Related Experiment Video

Updated: May 5, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.5K

Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126

Ying Y Lu1, Michael J Sweredoski, David Huss

  • 1Division of Chemistry and Chemical Engineering, MC 210-41, California Institute of Technology , 1200 East California Boulevard, Pasadena, California 91125, United States.

ACS Chemical Biology
|November 27, 2013
PubMed

Insights

MicroRNA-126 (miR-126) suppresses tumors by inhibiting metastasis. Researchers found miR-126 directly targets CD97, a receptor promoting cancer spread, revealing a new mechanism for miR-126

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Proteomics

Background:

  • MicroRNA-126 (miR-126) functions as a tumor suppressor, frequently downregulated in various cancers.
  • Downregulation of miR-126 correlates with increased cancer metastasis, highlighting its inhibitory role.
  • The precise molecular mechanisms underlying miR-126's tumor suppressive functions remain incompletely understood.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which miR-126 suppresses tumors.
  • To identify direct molecular targets of miR-126 in metastatic breast cancer cells.
  • To investigate the proteomic alterations induced by miR-126 overexpression.

Main Methods:

  • Utilized the human metastatic breast cancer cell line MDA-MB-231 for experiments.
  • Employed combined BONCAT and SILAC proteomic techniques for quantitative, time-resolved analysis.
  • Analyzed the proteomic response to miR-126 overexpression.

Main Results:

  • Identified CD97, a G-protein-coupled receptor (GPCR), as a novel direct target of miR-126.
  • Demonstrated that CD97 is a pro-metastatic factor involved in tumor cell invasion, endothelial cell migration, and angiogenesis.
  • Established a direct link between miR-126 downregulation and CD97 overexpression in cancer.

Conclusions:

  • miR-126 directly targets and inhibits the pro-metastatic receptor CD97.
  • This interaction provides a mechanistic explanation for miR-126's role in suppressing both cell-autonomous and non-cell-autonomous cancer progression.
  • The findings offer new therapeutic targets for inhibiting cancer metastasis by modulating the miR-126/CD97 axis.

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.1K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K